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Abstract
Background: Sepsis is a clinical syndrome associated with organ dysfunction due to a dysreg-
ulated host response to infection. Methicillin-resistant Staphylococcus aureus (MRSA) ventilator-
associated pneumonia (VAP) is a serious infection frequently associated with sepsis. The objec-
tives of this study were to define the incidence of sepsis and clinical failure in patients with MRSA
VAP.
Methods: This was a secondary analysis of the Improving Medicine through Pathway Assess-
ment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study database. VAP
was defined according to CDC criteria. MRSA VAP was considered when MRSA was isolated
from a tracheal aspirate or bronchoalveolar lavage. We used the 3rd International Consensus
Definitions for sepsis. The presence of clinical failure was evaluated at the 14 day follow-up and
defined as: 1) progression of baseline signs and symptoms of pneumonia, or 2) death. The Chi-
Square Trend Test was utilized to determine the association between the level of organ dysfunc-
tion and clinical failure.
Results: MRSA VAP was diagnosed in 205 patients with 138 (67%) presenting with sepsis.
Clinical failure occurred in 14% (8/57) of patients without sepsis. Clinical failure occurred in 18%
(13/73) of patients with sepsis and 1 organ dysfunction, in 28% (12/43) of patients with sepsis and
2 organ dysfunction, in 28% (5/18) of patients with sepsis and 3 organ dysfunction, and in 100%
(4/4) of patients with sepsis and 4 organ dysfunction (p= 0.01).
Conclusions: Sepsis is a frequent complication of MRSA VAP and the number of organ dysfunc-
tion correlates with clinical failure in these patients. Effective prevention and treatment of sepsis
and associated organ dysfunction is essential to avoid cumulative burden of disease in MRSA
VAP.
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1 Introduction
Ventilator-associated pneumonia (VAP) can occur in up to 8-28%
of intubated patients in the Intensive Care Unit (ICU).1 This infec-
tious complication of mechanical ventilation has been associated
with significant morbidity and mortality and linked to several risk
factors in the literature: severity of underlying comorbidities, in-
appropriate initial antibiotic regimen and multidrug resistant or-
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ganisms (MDRO).2 Amongst MDRO, methicillin-resistant Staphy-
lococcus aureus (MRSA) has emerged as a significant etiologic
agent in nosocomial infections worldwide.3 MRSA has been re-
ported as a common cause of VAP, along with Enterobacteriaceae
(usually the most common cause) and Pseudomonas aeruginosa
in several series.3–5 In this context, it is important to better un-
derstand the determinants of clinical failure in VAP. Septic shock
has been linked to VAP clinical failure, as measured by a mor-
tality predictive score, such as the Acute Physiology and Chronic
Health Evaluation II (APACHE II) Score.1,6,7 The magnitude of or-
gan dysfunction related to clinical failure, however, has not been
clearly defined. The objectives of this study were to determine if
there is an association between the number of organ dysfunction
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and clinical failure in patients with MRSA VAP and to better char-
acterize the type and frequency of organ dysfunction with MRSA
VAP and sepsis.
2 Materials and Methods
2.1 Study design
This was a secondary analysis of The Improving Medicine through
Pathway Assessment of Critical Therapy in Hospital-Acquired
Pneumonia (IMPACT-HAP) database, a multicenter, retrospective,
observational study of ICU patients with VAP due to MRSA treated
with linezolid or vancomycin. Patients were enrolled from 5 sites
in the United States: the University of Louisville Medical Center
(Louisville, KY); the Henry Ford Health System (Detroit, MI); the
University of Miami/Jackson Memorial Hospital (Miami, FL); the
Summa Health System (Akron, OH); and Michigan State Univer-
sity (East Lansing, MI). Data were collected from November 2008
through October 2012. Patient data were collected on a case re-
port form, entered into a web-based database, and transferred
electronically to the University of Louisville Clinical and Trans-
lational Research Support Center for data validation and quality.
The study was approved by the institutional review board at each
participating institution (University of Louisville Human Subjects
Protection Program Office; Summa Health System Institutional
Review Board; Michigan State University Human Research Pro-
tection Program; Henry Ford Health System Institutional Review
Board; University of Miami Human Subjects Research Office), all
of which waived the requirement for informed consent since this
was a retrospective observational study.
2.2 Study Definitions
2.2.1 Inclusion Criteria
• VAP was defined according to the Centers for Disease Con-
trol and Prevention National Healthcare Safety Network
surveillance definitions.8 VAP was considered to be due to
MRSA when MRSA was isolated from tracheal aspirates,
bronchoalveolar lavage (BAL) obtained by bronchoscopy, or
blinded BAL. Patients must have received more than 48
hours of either vancomycin or linezolid. Vancomycin was
dosed based on blood levels according to standard of care.
2.2.2 Exclusion Criteria
• Comfort care or a do not resuscitate order
• Clinical failure during the initial 48 hours of antibiotic ther-
apy
• In clinical practice, ICU physicians change antibiotics due
to their own preferences without the evidence of patients’
clinical deterioration. Patients were also excluded if there
was a switch from vancomycin to linezolid or vice versa after
48 hours in a patient without evidence of clinical failure.
Sepsis in patients with MRSA VAP was defined as the presence of
dysfunction of at least one organ system that was not attributable
to other causes at the time of VAP diagnosis.9
Organ dysfunction was defined according to specific organ sys-
tems, as follows:10,11
• Cardiovascular system: shock defined as arterial systolic
blood pressure <90 mmHg (shock for at least 1 hour, despite
adequate fluid resuscitation, adequate intravascular volume
status or the use of vasopressors in an attempt to maintain
a systolic blood pressure > 90 mmHg or a mean arterial
pressure of > 70 mmHg)
• Respiratory system: PaO2/FiO2 ratio < 250 (< 200 if the
lung was the only dysfunctional organ).
• Hematological system: thrombocytopenia (platelets
<100,000/mm3) or coagulation abnormality (INR> 1.5;
PTT 60 seconds)
• Renal system: increased creatinine >50% from baseline or
acute oliguria (< 0.5 ml/kg/h for >2 hours) or creatinine
increase > 0.5 mg/ dl.
2.3 Study Outcomes
The presence of clinical failure was evaluated at a 14-day follow-
up and was defined as: 1) progression of baseline signs and symp-
toms of pneumonia, or 2) death.
2.4 Statistical Analysis
Categorical variables were expressed as frequencies and percent-
ages and were compared between the two treatment groups using
Chi-square or Fisher’s exact tests. Continuous variables were ex-
pressed as means and standard deviations and were compared
between the two groups using the Mann-Whitney U-test or Stu-
dent’s t test. The Chi-square trend test was utilized to determine
the association between the magnitude of organ dysfunction and
clinical failure in MRSA VAP patients. P-values of ≤0.05 were
considered statistically significant in all analyses unless otherwise
specified.
3 Results
A total of 205 patients diagnosed with MRSA VAP were included
in this analysis. Sepsis was identified in 138 (67%) patients. Pa-
tients with organ system dysfunction presented with higher mean
APACHE II scores (p< 0.001) and had a higher rate of diabetes
mellitus (p 0.027) when compared to the patients without organ
dysfunction. Baseline characteristics of the study population are
further outlined in Table 1.
The percentage of patients with MRSA VAP clinical failure in-
creased along with the magnitude of organ dysfunction (Figure
1). Fourteen percent (8/57) of patients in the group without or-
gan dysfunction failed to respond to treatment, when compared
to 18% (13/73) in patients with single organ system dysfunction;
28% (12/43) in patients with dysfunction of two organ systems;
28% (5/18) with dysfunction of three organ systems and 100%
(4/4) in patients with dysfunction of four organ systems (p=
0.01).
The frequency of organ dysfunction is shown in Table 2.
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Table 1 Baseline characteristics of the study population
MRSA VAP MRSA VAP p-value
Sepsis: No Sepsis: Yes
Total 57 138
Age, mean (SD) 58 (16) 56 (16) 0.428
Males, n (%) 34 (60) 85 (62) 0.800
Cancer, n (%) 3 (5) 10 (7) 0.881
COPD, n (%) 4 (7) 20 (15) 0.148
ESLD, n (%) 1 (2) 10 (7) 0.222
ESRD, n (%) 2 (4) 5 (4) 0.999
Cardiac disease, n (%) 12 (23) 44 (32) 0.205
Vascular disease, n (%) 17 (30) 12 (9) 0.389
Diabetes mellitus, n (%) 8 (14) 40 (29) 0.027
Lung disease, n (%) 8 (14) 36 (26) 0.067
CPIS day 0, mean (SD) 6 (2) 6 (2) 1.000
APACHE II score, mean (SD) 17 (5) 21 (7) < 0.001
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, Chronic Obstructive
Pulmonary Disease; CPIS, Clinical Pulmonary Infection Score; ESLD, End-Stage Liver disease;
ESRD, End-Stage Renal Disease
Fig. 1 Percentage of patients with clinical failure according to the number of failing organ systems
4 Discussion
This study analyzed the correlation between MRSA VAP clinical
failure and specific organ system dysfunction.
The true impact of VAP on mortality and the role of MDRO in out-
comes of this disease process remain poorly defined. Attributable
mortality rates for VAP are still debatable and described as being
between 33-50% in some series.12,13 Melsen et al, however, did
not find evidence of attributable mortality due to VAP in patients
with trauma or acute respiratory distress syndrome (ARDS).14
There was such evidence in other patient groups, although un-
able to be quantified due to heterogeneity of study results and
pooled analysis. Conflicting results have also been found regard-
ing the role of MDRO on VAP mortality and outcomes, largely
due to overlap of confounding factors, such as associated comor-
bidities and organ failure in severe and advanced presentations
of VAP.
Several studies have explored early predictors of infection recur-
rence and death in patients with VAP. Female sex, age over 70,
disease severity at onset of VAP and persistent fever have been
identified as indicators of poor outcomes.2 Age over 70, higher
APACHE II scores, and associated comorbidities have been de-
scribed as risk factors for VAP clinical failure in some series.1
Scores to predict 30-day mortality in hospitalized patients, such
as the APACHE II score, have been noted to be early and inde-
pendent indicators of mortality and clinical failure in VAP pa-
tients.1,6,7,15 In our study, patients with higher APACHE II scores
were more likely to experience MRSA VAP clinical failure.
The presence of generalized, multi-organ failure has been linked
to 30-day all-cause mortality in MRSA pneumonia.3 In terms of
the impact of specific organ system failure on VAP outcomes,
Gursel et al described a 38% incidence of acute renal failure
(ARF) in this patient population.16 High APACHE scores, MDRO
and sepsis were independent risk factors for development of ARF
during VAP episodes in that series. The renal system was found
to be the second most affected organ system in our study.
In face of the significant morbidity associated with MRSA VAP,
identifying and defining modifiable risk factors and patients at a
potential risk for poor outcomes becomes essential. This strategy
would allow for early and aggressive intervention and treatment
of organ dysfunction in VAP.
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Table 2 Type of organ system dysfunction







Sepsis and increasing magnitude of organ dysfunction were ob-
served in 67% of our patients with MRSA VAP. The most common
organ systems to fail were pulmonary, renal, metabolic, hemato-
logic and cardiovascular, respectively. It is uncertain if this dis-
tribution is seen mainly in sepsis subsequent to VAP or is simi-
lar in sepsis due to other infections. The cumulative burden of
organ dysfunction leading to clinical failure makes effective pre-
vention and treatment of these conditions essential in the context
of MRSA VAP.
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